Cited by 67Lipid metabolism and biosynthesisFatty Acid Research and HealthLipid metabolism and disorders

Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease

Open access
Hui, David Y.·2016·Current Opinion in Lipidology

Abstract

PURPOSE OF REVIEW: Phospholipids are major constituents in the intestinal lumen after meal consumption. This article highlights current literature suggesting the contributory role of intestinal phospholipid metabolism toward cardiometabolic disease manifestation. RECENT FINDINGS: Group 1b phospholipase A2 (PLA2g1b) catalyzes phospholipid hydrolysis in the intestinal lumen. The digestive product lysophospholipid, particularly lysophosphatidylcholine (LPC), has a direct role in mediating chylomicron assembly and secretion. The LPC in the digestive tract is further catabolized into lysophosphatidic acid and choline via autotaxin-mediated and autotaxin-independent mechanisms. The LPC and lysophosphatidic acid absorbed through the digestive tract and transported to the plasma directly promote systemic inflammation and cell dysfunction, leading to increased risk of cardiovascular disease and obesity/diabetes. The choline moiety generated in the digestive tract can also be used by gut bacteria to generate trimethylamine, which is subsequently transported to the liver and oxidized into trimethylamine-N-oxide that also enhances atherosclerosis and cardiovascular abnormalities. SUMMARY: Products of phospholipid metabolism in the intestine through PLA2g1b and autotaxin-mediated pathways directly contribute to cardiometabolic diseases through multiple mechanisms. The implication of these studies is that therapeutic inhibition of PLA2g1b and autotaxin in the digestive tract may be a viable approach for cardiovascular and metabolic disease intervention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mol.0000000000000334

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hui, D. Y.
Affiliations
University of Cincinnati (US)
Corresponding author
Hui, David Y.
Venue
Current Opinion in Lipidology
Published
2016-10
Volume
27
Issue
5
Pages
507-512
ISSN
  • 0957-9672 (ISSN-L)
  • 1473-6535
OpenAlex
W2501691835
Cited by
67
References
37
Citations by year
2026: 5 · 2025: 7 · 2024: 8 · 2023: 9 · 2022: 8 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 6 · 2017: 3 · 2016: 1
FWCI
0.63
Type
journal article
Language
en
Open access
Locations
  • Current Opinion in Lipidology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Heart, Lung, and Blood Institute (R01HL131028, R01HL118001)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK069967, R01DK074932, R01DK112657)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
lysophospholipids, lysophosphatidylcholine, lysophosphatidic acid, autotaxin, chylomicron assembly, choline, trimethylamine, trimethylamine N-oxide, gut microbiota, cardiovascular disease, obesity, diabetes mellitus, systemic inflammation, atherosclerosis
MeSH terms
Animals, Choline, Humans, Intestinal Mucosa, Lysophospholipids, Metabolic Diseases, Myocardium

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review